Close
May 27th, 2008

Octapharma will sponsor two satellite symposia at the upcoming ISBT Congress, June 7 – 12, 2008 in Macau SAR, China


The XXXth International Congress of the International Society of Blood Transfusion will be convened in the Macao SAR, China from June 7 to June 12, 2008. The International Congress of ISBT will feature scientific programs that address contemporary issues and the latest scientific developments in Transfusion Medicine.

Octapharma will be present at this congress with a 54 sqm booth, No. 149, where we will provide information on all our Intensive Care products. This includes:
  • octaplas®, biopharmaceutical alternative of plasma for infusion

  • octaplex®, 2nd generation Prothrombin Complex Concentrate

  • atenativ®, pure Antithrombin lll concentrate, free of heparin

  • albumin, protein solution for restoration and maintenance of circulating blood

  • wilate®, new generation, high purity, VWF/FVIII-concentrate

Delegates are invited to visit our booth, to discuss our products and to participate in our ICU challenge, an interactive quiz to highlight our product characteristics.

This year we will easily be recognized, as our booth will display a large 3D model of the Matterhorn, the most famous mountain in Switzerland.



We will be sponsoring the following two lunchtime symposia on June 8 and June 11:

“Optimization of the use of blood components within the hospital: Strategies and Trends”
June 8, 2008 12:15 – 13:45h

Blood components are scarce products, which are used, in many life-threatening conditions. Blood component audits and surveys have shown that blood components are not always used as indicated. This symposium will focus on the guidelines, audit strategies, awareness on appropriate use of blood component and through alternative therapies which can eventually results in better outcomes for the patients. The speakers will explain how blood component audits can be setup and how such strategies will help in optimizing the use of blood components in a hospital.


“Prion safety and Transfusion Plasma”
June 11, 2008 12:45 – 13:45h

Since the first cases of vCJD were reported, major concerns were raised on the possible transmission of the disease through infusion of plasma. This has lead some regulatory authorities to enforce special measures to reduce the load of prions in all biopharmaceutical plasma derived products, including biopharmaceutical approved solvent-detergent treated (octaplas®) plasma for transfusion. This symposium will focus on these concerns and discuss the actual risk of prions in plasma and explain the implementation of a prion reduction step for a licensed solvent-detergent   treated plasma like octaplas®


We look forward to seeing you at our booth #149 and at our two symposia


© Octapharma AG, 2008